EMA Authorised: Livmarli (Maralixibat chloride) — Mirum Pharmaceuticals International B.V.

View source ↗

Summary

The European Medicines Agency has authorised Livmarli (maralixibat) for Alagille syndrome, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LIVMARLI (Maralixibat chloride)

Snippet

Status: Authorised. Therapeutic area: Alagille Syndrome. MAH: Mirum Pharmaceuticals International B.V.. Decision date: 18/02/2026. Orphan medicine